ShanghaiApril 22, 2026 /PRNewswire/ — On the morning of April 20, the ceremony for Eisai (China) Investment Co., Ltd. (hereinafter referred to as “Eisai China”) to settle in the Suhewan Center and the unveiling ceremony for Eisai Chuangtuo Technology Services (Shanghai) Co., Ltd. (hereinafter referred to as “Eisai Chuangtuo”) were held at the Suhewan Center in Jing’an District. Attendees included Long Wanli, Deputy District Mayor of Jing’an District, Shanghai; Cao Hongming, Director of the Biopharmaceutical Department of the Shanghai Municipal Science and Technology Commission; Feng Yanhui, Chairman of Eisai China; Zhou Yang, President of Eisai China; and others. Representatives from relevant departments of Jing’an District, including the Science, Technology and Economy Commission; Health Commission; Medical Insurance Bureau; Investment Promotion Bureau; Market Supervision Administration; Beizhan Sub-district; Shanghai New Nanxi (Group) Co., Ltd.; and Shanghai Suhewan Cultural, Creative and Technology (Group) Co., Ltd., participated in the event.
Eisai China Welcomes Leaders for Guidance at Suhewan Center
Global Innovation • Synchronized in China: Eisai China Opens a New Chapter of Development in Shanghai
During the event, Long Wanli, Cao Hongming, Feng Yanhui, and Zhou Yang jointly unveiled the plaque for Eisai Chuangtuo, marking a new level in Eisai China’s development capabilities in Shanghai.
Eisai Chuangtuo Unveiling Ceremony
In his speech, Feng Yanhui stated that 2026 marks the 35th anniversary of Eisai’s entry into the Chinese market. Since establishing roots in China in 1991, Eisai China has consistently adhered to the corporate philosophy of “hhc” (human health care), committed to bringing globally leading innovative medicines to Chinese patients. Settling in the Suhewan Center is a crucial step for Eisai China to deepen localized operations, expand innovative cooperation functions, and achieve the transformation from a branch to an independent legal entity. In the future, guided by the strategy of “Global Innovation, Local Realization,” Eisai China will fully leverage its core function as an “Innovative Drug Introduction Hub” to enable Chinese patients to benefit from global innovative achievements simultaneously.
Long Wanli Presents a Settlement Gift to Eisai China on Behalf of Jing’an District People’s Government
Long Wanli, on behalf of the Jing’an District People’s Government, presented a settlement gift to Eisai China, warmly welcoming Eisai China’s choice of Jing’an and Suhewan. He stated that Jing’an District will continue to optimize the business environment and fully support Eisai China in achieving higher-quality development in Jing’an.
Government-Enterprise Collaboration: Discussing High-Quality Development of Biopharmaceuticals
Following the unveiling ceremony, government and enterprise representatives held a symposium, engaging in in-depth exchanges on the theme of “Innovation Leadership • Shared Benefits for People’s Livelihood” for biopharmaceutical enterprises.
During the symposium, relevant leaders from Eisai China introduced the progress of the company’s “Global Innovation, Local Realization” strategy. Currently, Eisai China has established a rich pipeline of innovative products in key areas such as neuroscience, oncology specialty drugs, and digestive/metabolic diseases. Innovative products like Leqembi® (lecanemab) for early Alzheimer’s disease, Dayvigo® (lemborexant) for insomnia, and Uloric® (febuxostat) for gout with hyperuricemia have been successively launched in China. This year, Leqembi® subcutaneous injection and Lacteol® for diarrhea will also enter the Chinese market, continuously strengthening the product portfolio. With the continuous expansion of its business scale, Eisai China has become a key engine and important pillar driving Eisai’s global innovation and performance growth.
Eisai China stated that the company is actively promoting a capability leap from “introduction” to “transformation,” continuously enhancing the clinical value and patient accessibility of imported drugs in the Chinese market. Currently, the company is actively exploring an integrated solution for the “early screening, early diagnosis, and early treatment” of Alzheimer’s disease. By combining blood test early screening technology, government guidance, and corporate profit concessions, it aims to explore and form a benefit-sharing model of “government support, enterprise participation, and multi-party win-win,” helping to improve the accessibility of diagnosis and treatment for Alzheimer’s patients and tangibly benefiting people’s livelihood.
Cao Hongming affirmed Eisai China’s continuous investment in neuroscience and its introduction of global innovative achievements. He pointed out that biopharmaceuticals are a leading industry prioritized for development in Shanghai. The Municipal Science and Technology Commission will continue to support the R&D, market launch, and international development of innovative drugs and medical devices. He expressed hope that Eisai China would further leverage its role as an “Innovative Drug Introduction Hub” to benefit Chinese patients with more globally leading innovative achievements.
Long Wanli stated that Jing’an District is accelerating the construction of a development pattern of “International Jing’an, Excellent Urban Area,” with life and health being a key industrial direction for the region. The settlement of Eisai China has injected new momentum into the development of Jing’an’s biopharmaceutical industry. Jing’an will make every effort to provide service support, assisting Eisai China in achieving greater development in Jing’an.
Representatives from relevant departments of Jing’an District, including the Science, Technology and Economy Commission; Health Commission; Medical Insurance Bureau; and Market Supervision Administration, conducted exchanges and connections with the enterprise on topics such as industrial policy, clinical application, medical insurance linkage, and compliant development.
Deepening Roots in Jing’an: Building a New High Ground for the Biopharmaceutical Industry
The settlement of Eisai China in the Suhewan Center is another important achievement of Jing’an District’s continuous optimization of the business environment and promotion of high-quality development in the biopharmaceutical industry. As a globally leading innovative pharmaceutical company, and to better adapt to the group’s strategic development needs, further optimize resource allocation, and enhance management efficiency, Eisai Chuangtuo will serve as an important platform for Eisai China’s innovative business in Shanghai. Meanwhile, Eisai China’s presence in Jing’an District’s Suhewan area will effectively drive the agglomeration of the regional biopharmaceutical industry chain and enhance the industrial capabilities of the Suhewan functional area.